Abridge Secures $150M to Expand GenAI, Partners with Yale New Haven Health System

What You Should Know:

– Abridge, the leading force in generative AI for clinical documentation, announced today a staggering $150 million Series C funding round led by Lightspeed Venture Partners. The funding also includes participation from new and existing investors like Redpoint Ventures, IVP, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Mass General Brigham Artificial Intelligence and Digital Innovation Fund (AIDIF), Kaiser Permanente Ventures, and CVS Health Ventures.

– The funding, just four months after their $30M Series B round, stands as one of the largest in generative AI for healthcare and underscores the immense potential of Abridge’s technology.

Yale New Haven Health System Adopts Abridge

Coinciding with the funding news, Abridge announced a significant partnership with Yale New Haven Health System, the largest healthcare system in Connecticut. This agreement will provide thousands of Yale New Haven clinicians with access to Abridge’s AI-powered documentation platform. The initial focus will be on reducing documentation burden and allowing clinicians to dedicate more time to patient care.

Building Trust with “Linked Evidence” Technology

Abridge sets itself apart with its unique “Linked Evidence” feature, which maps AI-generated summaries directly to their source data, ensuring transparency and building trust among healthcare professionals. This auditable approach is crucial for the responsible deployment of AI in sensitive medical environments.

Pushing Boundaries in Generative AI

With the new funding, Abridge plans to invest heavily in fundamental research, developing next-generation AI models based on vast amounts of healthcare data. This will fuel continued improvement of their existing products and pave the way for exciting new possibilities in the future.

“We are grateful to be partnering with iconic institutions that share our dedication to improving the lives of patients and clinicians,” said Dr. Shiv Rao, CEO and Founder of Abridge. “This company was founded on the premise that clinician-patient conversations are at the core of all healthcare. Already, this information is powering a revolution in AI-based documentation. In the future, it will open new pathways to improve patient outcomes. Realizing this vision requires world-class talent and formidable compute resources. We are now uniquely positioned to build the AI platform that brings this vision to life.”